biopharma-reporter6h
Promising early Parkinson’s immunotherapy results for AC Immune
The interim phase 2 trial results show a good immune response in participants and the therapy is well tolerated to date.
biopharma-reporter6h
SEKISUI Diagnostics completes £15.7M expansion to boost biopharma manufacturing capacity
New cGMP fermentation facility in the UK set to meet growing demand for drug substance production, supporting biopharma ...
biopharma-reporter11h
Alentis raises $181 million to advance ADCs to the clinic
The Series D financing will support the clinical development of two ADCs.
biopharma-reporter2d
AbbVie’s schizophrenia candidate fails in two phase 2 trials
Emraclidine was expected to be a competitor to Bristol Myers Squibb’s recently approved Cobenfy, but trial results put its ...
biopharma-reporter2d
FDA removes clinical hold on Novavax’s COVID-19-influenza combo vaccine
The FDA had put a clinical hold on Novavax’s COVID-19-influenza combo vaccine after an adverse event in a patient.
biopharma-reporter7d
Sarepta discontinues development of Duchenne ASO treatment vesleteplirsen
The US biopharma will discontinue development of the Exondys 51 (eteplirsen) follow up treatment to focus on other treatment ...
biopharma-reporter7d
Aditum Bio and Leads Biolabs join forces in new company to fight autoimmune diseases
The U.S. company Aditum Bio and Chinese company Leads Biolabs today announced that they have founded Oblenio Bio, a new ...
biopharma-reporter9d
EMA accepts Alvotech and Advanz Pharma’s Marketing Authorization Application for biosimilar of J&J’s Simponi
The Simponi biosimilar, AVT05, has shown positive top-line results in patients with moderate to severe rheumatoid arthritis.